nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—HRH1—atherosclerosis	0.414	1	CbGaD
Iloperidone—CYP3A7—Simvastatin—atherosclerosis	0.0355	0.096	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0355	0.096	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0348	0.0939	CbGbCtD
Iloperidone—CYP3A7—Lovastatin—atherosclerosis	0.0348	0.0939	CbGbCtD
Iloperidone—CYP3A5—Rosuvastatin—atherosclerosis	0.0287	0.0774	CbGbCtD
Iloperidone—CYP3A5—Simvastatin—atherosclerosis	0.0267	0.072	CbGbCtD
Iloperidone—CYP3A5—Pravastatin—atherosclerosis	0.0261	0.0705	CbGbCtD
Iloperidone—CYP3A5—Lovastatin—atherosclerosis	0.0261	0.0705	CbGbCtD
Iloperidone—CYP2D6—Niacin—atherosclerosis	0.0207	0.0559	CbGbCtD
Iloperidone—CYP2D6—Simvastatin—atherosclerosis	0.0164	0.0441	CbGbCtD
Iloperidone—CYP2D6—Lovastatin—atherosclerosis	0.016	0.0432	CbGbCtD
Iloperidone—CYP2D6—Pravastatin—atherosclerosis	0.016	0.0432	CbGbCtD
Iloperidone—CYP3A4—Ezetimibe—atherosclerosis	0.0112	0.0302	CbGbCtD
Iloperidone—CYP3A4—Rosuvastatin—atherosclerosis	0.0112	0.0302	CbGbCtD
Iloperidone—CYP3A4—Simvastatin—atherosclerosis	0.0104	0.0281	CbGbCtD
Iloperidone—CYP3A4—Lovastatin—atherosclerosis	0.0102	0.0275	CbGbCtD
Iloperidone—CYP3A4—Pravastatin—atherosclerosis	0.0102	0.0275	CbGbCtD
Iloperidone—Lenticular opacities—Lovastatin—atherosclerosis	0.00501	0.0508	CcSEcCtD
Iloperidone—Lenticular opacities—Simvastatin—atherosclerosis	0.00469	0.0475	CcSEcCtD
Iloperidone—Lenticular opacities—Pravastatin—atherosclerosis	0.00424	0.043	CcSEcCtD
Iloperidone—HTR2A—arteriole—atherosclerosis	0.00257	0.112	CbGeAlD
Iloperidone—HTR7—vein—atherosclerosis	0.00245	0.107	CbGeAlD
Iloperidone—Paliperidone—HRH1—atherosclerosis	0.00176	0.537	CrCbGaD
Iloperidone—Faecal incontinence—Niacin—atherosclerosis	0.00171	0.0174	CcSEcCtD
Iloperidone—Cholelithiasis—Ezetimibe—atherosclerosis	0.00159	0.0161	CcSEcCtD
Iloperidone—HTR2A—vein—atherosclerosis	0.00153	0.067	CbGeAlD
Iloperidone—Blood disorder—Rosuvastatin—atherosclerosis	0.00142	0.0144	CcSEcCtD
Iloperidone—Cholelithiasis—Niacin—atherosclerosis	0.00139	0.0141	CcSEcCtD
Iloperidone—Hypothyroidism—Niacin—atherosclerosis	0.00135	0.0136	CcSEcCtD
Iloperidone—Risperidone—HRH1—atherosclerosis	0.00131	0.4	CrCbGaD
Iloperidone—HTR1D—artery—atherosclerosis	0.00126	0.0549	CbGeAlD
Iloperidone—Endocrine disorder—Simvastatin—atherosclerosis	0.00113	0.0115	CcSEcCtD
Iloperidone—Gastrooesophageal reflux disease—Ezetimibe—atherosclerosis	0.00109	0.0111	CcSEcCtD
Iloperidone—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00106	0.0108	CcSEcCtD
Iloperidone—Cataract—Lovastatin—atherosclerosis	0.00106	0.0107	CcSEcCtD
Iloperidone—HTR2A—hindlimb—atherosclerosis	0.00102	0.0445	CbGeAlD
Iloperidone—HTR7—artery—atherosclerosis	0.001	0.0437	CbGeAlD
Iloperidone—Breast pain—Niacin—atherosclerosis	0.00099	0.01	CcSEcCtD
Iloperidone—Cataract—Simvastatin—atherosclerosis	0.000988	0.01	CcSEcCtD
Iloperidone—HTR1D—blood vessel—atherosclerosis	0.000978	0.0428	CbGeAlD
Iloperidone—Renal failure acute—Rosuvastatin—atherosclerosis	0.000933	0.00946	CcSEcCtD
Iloperidone—Amnesia—Rosuvastatin—atherosclerosis	0.000917	0.0093	CcSEcCtD
Iloperidone—Gynaecomastia—Lovastatin—atherosclerosis	0.0009	0.00913	CcSEcCtD
Iloperidone—Cataract—Pravastatin—atherosclerosis	0.000893	0.00906	CcSEcCtD
Iloperidone—HTR2A—appendage—atherosclerosis	0.000873	0.0382	CbGeAlD
Iloperidone—HTR7—endothelium—atherosclerosis	0.000845	0.0369	CbGeAlD
Iloperidone—Gynaecomastia—Simvastatin—atherosclerosis	0.000842	0.00854	CcSEcCtD
Iloperidone—Fluid retention—Niacin—atherosclerosis	0.00082	0.00832	CcSEcCtD
Iloperidone—HTR7—blood vessel—atherosclerosis	0.000779	0.0341	CbGeAlD
Iloperidone—Breast disorder—Rosuvastatin—atherosclerosis	0.000778	0.00789	CcSEcCtD
Iloperidone—Amnesia—Lovastatin—atherosclerosis	0.000777	0.00788	CcSEcCtD
Iloperidone—Amnesia—Ezetimibe—atherosclerosis	0.000762	0.00773	CcSEcCtD
Iloperidone—Gynaecomastia—Pravastatin—atherosclerosis	0.000761	0.00772	CcSEcCtD
Iloperidone—Amnesia—Simvastatin—atherosclerosis	0.000727	0.00737	CcSEcCtD
Iloperidone—Renal failure acute—Pravastatin—atherosclerosis	0.000669	0.00678	CcSEcCtD
Iloperidone—Amnesia—Pravastatin—atherosclerosis	0.000657	0.00666	CcSEcCtD
Iloperidone—Breast disorder—Ezetimibe—atherosclerosis	0.000647	0.00656	CcSEcCtD
Iloperidone—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00064	0.00649	CcSEcCtD
Iloperidone—Gastritis—Ezetimibe—atherosclerosis	0.000634	0.00643	CcSEcCtD
Iloperidone—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000628	0.00637	CcSEcCtD
Iloperidone—HTR2A—artery—atherosclerosis	0.000624	0.0273	CbGeAlD
Iloperidone—Disturbance in sexual arousal—Niacin—atherosclerosis	0.000622	0.00631	CcSEcCtD
Iloperidone—Affect lability—Pravastatin—atherosclerosis	0.000608	0.00616	CcSEcCtD
Iloperidone—Abdominal discomfort—Lovastatin—atherosclerosis	0.000605	0.00613	CcSEcCtD
Iloperidone—Gastritis—Simvastatin—atherosclerosis	0.000604	0.00613	CcSEcCtD
Iloperidone—Urinary retention—Niacin—atherosclerosis	0.000596	0.00605	CcSEcCtD
Iloperidone—Mood swings—Pravastatin—atherosclerosis	0.000585	0.00593	CcSEcCtD
Iloperidone—Erectile dysfunction—Lovastatin—atherosclerosis	0.000581	0.00589	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000575	0.00583	CcSEcCtD
Iloperidone—Orthostatic hypotension—Niacin—atherosclerosis	0.000573	0.00581	CcSEcCtD
Iloperidone—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00057	0.00578	CcSEcCtD
Iloperidone—Abdominal discomfort—Simvastatin—atherosclerosis	0.000566	0.00574	CcSEcCtD
Iloperidone—Nasopharyngitis—Pravastatin—atherosclerosis	0.000552	0.0056	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000549	0.00556	CcSEcCtD
Iloperidone—Erectile dysfunction—Simvastatin—atherosclerosis	0.000544	0.00551	CcSEcCtD
Iloperidone—Arrhythmia—Rosuvastatin—atherosclerosis	0.000532	0.0054	CcSEcCtD
Iloperidone—HTR2A—endothelium—atherosclerosis	0.000527	0.023	CbGeAlD
Iloperidone—Mental disorder—Rosuvastatin—atherosclerosis	0.000522	0.00529	CcSEcCtD
Iloperidone—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000522	0.00529	CcSEcCtD
Iloperidone—HTR1D—connective tissue—atherosclerosis	0.000501	0.0219	CbGeAlD
Iloperidone—Erectile dysfunction—Niacin—atherosclerosis	0.000499	0.00506	CcSEcCtD
Iloperidone—Dysuria—Pravastatin—atherosclerosis	0.000499	0.00506	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000496	0.00503	CcSEcCtD
Iloperidone—Erectile dysfunction—Pravastatin—atherosclerosis	0.000491	0.00498	CcSEcCtD
Iloperidone—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000487	0.00494	CcSEcCtD
Iloperidone—HTR2A—blood vessel—atherosclerosis	0.000486	0.0212	CbGeAlD
Iloperidone—Weight increased—Pravastatin—atherosclerosis	0.000486	0.00492	CcSEcCtD
Iloperidone—Weight decreased—Pravastatin—atherosclerosis	0.000483	0.0049	CcSEcCtD
Iloperidone—Stomatitis—Niacin—atherosclerosis	0.000471	0.00478	CcSEcCtD
Iloperidone—CYP3A7—liver—atherosclerosis	0.00047	0.0205	CbGeAlD
Iloperidone—Angiopathy—Ezetimibe—atherosclerosis	0.000449	0.00456	CcSEcCtD
Iloperidone—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000446	0.00453	CcSEcCtD
Iloperidone—Arthralgia—Rosuvastatin—atherosclerosis	0.000442	0.00448	CcSEcCtD
Iloperidone—Myalgia—Rosuvastatin—atherosclerosis	0.000442	0.00448	CcSEcCtD
Iloperidone—HTR1D—cardiovascular system—atherosclerosis	0.000436	0.0191	CbGeAlD
Iloperidone—Mental disorder—Ezetimibe—atherosclerosis	0.000434	0.0044	CcSEcCtD
Iloperidone—Malnutrition—Ezetimibe—atherosclerosis	0.000431	0.00437	CcSEcCtD
Iloperidone—Confusional state—Rosuvastatin—atherosclerosis	0.000427	0.00433	CcSEcCtD
Iloperidone—Muscle spasms—Lovastatin—atherosclerosis	0.000423	0.00429	CcSEcCtD
Iloperidone—Infection—Rosuvastatin—atherosclerosis	0.000421	0.00427	CcSEcCtD
Iloperidone—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000415	0.00421	CcSEcCtD
Iloperidone—Muscle spasms—Ezetimibe—atherosclerosis	0.000415	0.0042	CcSEcCtD
Iloperidone—Vision blurred—Lovastatin—atherosclerosis	0.000414	0.0042	CcSEcCtD
Iloperidone—Mental disorder—Simvastatin—atherosclerosis	0.000414	0.0042	CcSEcCtD
Iloperidone—Tremor—Lovastatin—atherosclerosis	0.000412	0.00418	CcSEcCtD
Iloperidone—Eye disorder—Niacin—atherosclerosis	0.000405	0.00411	CcSEcCtD
Iloperidone—Tinnitus—Niacin—atherosclerosis	0.000404	0.0041	CcSEcCtD
Iloperidone—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000399	0.0175	CbGeAlD
Iloperidone—HTR7—connective tissue—atherosclerosis	0.000399	0.0175	CbGeAlD
Iloperidone—Anaemia—Ezetimibe—atherosclerosis	0.000399	0.00404	CcSEcCtD
Iloperidone—Tinnitus—Pravastatin—atherosclerosis	0.000398	0.00404	CcSEcCtD
Iloperidone—Cardiac disorder—Pravastatin—atherosclerosis	0.000396	0.00402	CcSEcCtD
Iloperidone—Muscle spasms—Simvastatin—atherosclerosis	0.000395	0.00401	CcSEcCtD
Iloperidone—Vertigo—Lovastatin—atherosclerosis	0.000395	0.00401	CcSEcCtD
Iloperidone—Angiopathy—Niacin—atherosclerosis	0.000394	0.00399	CcSEcCtD
Iloperidone—Leukopenia—Lovastatin—atherosclerosis	0.000394	0.00399	CcSEcCtD
Iloperidone—Vision blurred—Simvastatin—atherosclerosis	0.000388	0.00393	CcSEcCtD
Iloperidone—Arrhythmia—Niacin—atherosclerosis	0.000388	0.00393	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000386	0.00391	CcSEcCtD
Iloperidone—Tremor—Simvastatin—atherosclerosis	0.000385	0.00391	CcSEcCtD
Iloperidone—Arrhythmia—Pravastatin—atherosclerosis	0.000382	0.00387	CcSEcCtD
Iloperidone—Palpitations—Ezetimibe—atherosclerosis	0.000381	0.00386	CcSEcCtD
Iloperidone—Paraesthesia—Rosuvastatin—atherosclerosis	0.00038	0.00386	CcSEcCtD
Iloperidone—Anaemia—Simvastatin—atherosclerosis	0.00038	0.00385	CcSEcCtD
Iloperidone—Malnutrition—Niacin—atherosclerosis	0.000378	0.00383	CcSEcCtD
Iloperidone—Arthralgia—Lovastatin—atherosclerosis	0.000374	0.0038	CcSEcCtD
Iloperidone—Myalgia—Lovastatin—atherosclerosis	0.000374	0.0038	CcSEcCtD
Iloperidone—Vertigo—Simvastatin—atherosclerosis	0.000369	0.00375	CcSEcCtD
Iloperidone—Leukopenia—Simvastatin—atherosclerosis	0.000368	0.00373	CcSEcCtD
Iloperidone—Arthralgia—Ezetimibe—atherosclerosis	0.000367	0.00372	CcSEcCtD
Iloperidone—Myalgia—Ezetimibe—atherosclerosis	0.000367	0.00372	CcSEcCtD
Iloperidone—Dry mouth—Lovastatin—atherosclerosis	0.000366	0.00371	CcSEcCtD
Iloperidone—HTR1A—cardiovascular system—atherosclerosis	0.000364	0.0159	CbGeAlD
Iloperidone—Muscle spasms—Niacin—atherosclerosis	0.000363	0.00368	CcSEcCtD
Iloperidone—Confusional state—Lovastatin—atherosclerosis	0.000362	0.00367	CcSEcCtD
Iloperidone—Dry mouth—Ezetimibe—atherosclerosis	0.000359	0.00364	CcSEcCtD
Iloperidone—SIGMAR1—adipose tissue—atherosclerosis	0.000359	0.0157	CbGeAlD
Iloperidone—Muscle spasms—Pravastatin—atherosclerosis	0.000357	0.00362	CcSEcCtD
Iloperidone—Infection—Lovastatin—atherosclerosis	0.000356	0.00361	CcSEcCtD
Iloperidone—Vision blurred—Niacin—atherosclerosis	0.000356	0.00361	CcSEcCtD
Iloperidone—Confusional state—Ezetimibe—atherosclerosis	0.000355	0.0036	CcSEcCtD
Iloperidone—Vision blurred—Pravastatin—atherosclerosis	0.00035	0.00355	CcSEcCtD
Iloperidone—Arthralgia—Simvastatin—atherosclerosis	0.00035	0.00355	CcSEcCtD
Iloperidone—Myalgia—Simvastatin—atherosclerosis	0.00035	0.00355	CcSEcCtD
Iloperidone—Infection—Ezetimibe—atherosclerosis	0.00035	0.00355	CcSEcCtD
Iloperidone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000349	0.00354	CcSEcCtD
Iloperidone—Tremor—Pravastatin—atherosclerosis	0.000348	0.00353	CcSEcCtD
Iloperidone—HTR7—cardiovascular system—atherosclerosis	0.000347	0.0152	CbGeAlD
Iloperidone—Nervous system disorder—Ezetimibe—atherosclerosis	0.000345	0.0035	CcSEcCtD
Iloperidone—Anaemia—Pravastatin—atherosclerosis	0.000344	0.00348	CcSEcCtD
Iloperidone—Vertigo—Niacin—atherosclerosis	0.000339	0.00344	CcSEcCtD
Iloperidone—Confusional state—Simvastatin—atherosclerosis	0.000338	0.00343	CcSEcCtD
Iloperidone—Leukopenia—Niacin—atherosclerosis	0.000338	0.00343	CcSEcCtD
Iloperidone—Oedema—Simvastatin—atherosclerosis	0.000336	0.0034	CcSEcCtD
Iloperidone—ADRA1A—cardiovascular system—atherosclerosis	0.000335	0.0147	CbGeAlD
Iloperidone—Vertigo—Pravastatin—atherosclerosis	0.000334	0.00339	CcSEcCtD
Iloperidone—Palpitations—Niacin—atherosclerosis	0.000334	0.00338	CcSEcCtD
Iloperidone—Infection—Simvastatin—atherosclerosis	0.000333	0.00338	CcSEcCtD
Iloperidone—Leukopenia—Pravastatin—atherosclerosis	0.000333	0.00337	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000327	0.00332	CcSEcCtD
Iloperidone—Paraesthesia—Lovastatin—atherosclerosis	0.000322	0.00327	CcSEcCtD
Iloperidone—Myalgia—Niacin—atherosclerosis	0.000321	0.00326	CcSEcCtD
Iloperidone—Arthralgia—Niacin—atherosclerosis	0.000321	0.00326	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000321	0.00325	CcSEcCtD
Iloperidone—Dyspnoea—Lovastatin—atherosclerosis	0.00032	0.00324	CcSEcCtD
Iloperidone—Myalgia—Pravastatin—atherosclerosis	0.000317	0.00321	CcSEcCtD
Iloperidone—Arthralgia—Pravastatin—atherosclerosis	0.000317	0.00321	CcSEcCtD
Iloperidone—Paraesthesia—Ezetimibe—atherosclerosis	0.000316	0.0032	CcSEcCtD
Iloperidone—Dry mouth—Niacin—atherosclerosis	0.000314	0.00319	CcSEcCtD
Iloperidone—Dyspnoea—Ezetimibe—atherosclerosis	0.000314	0.00318	CcSEcCtD
Iloperidone—Fatigue—Lovastatin—atherosclerosis	0.000309	0.00314	CcSEcCtD
Iloperidone—Oedema—Niacin—atherosclerosis	0.000308	0.00313	CcSEcCtD
Iloperidone—Confusional state—Pravastatin—atherosclerosis	0.000306	0.0031	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000306	0.0031	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000304	0.00308	CcSEcCtD
Iloperidone—Asthenia—Rosuvastatin—atherosclerosis	0.000304	0.00308	CcSEcCtD
Iloperidone—Oedema—Pravastatin—atherosclerosis	0.000303	0.00308	CcSEcCtD
Iloperidone—Fatigue—Ezetimibe—atherosclerosis	0.000303	0.00308	CcSEcCtD
Iloperidone—Infection—Pravastatin—atherosclerosis	0.000301	0.00306	CcSEcCtD
Iloperidone—Paraesthesia—Simvastatin—atherosclerosis	0.000301	0.00306	CcSEcCtD
Iloperidone—Tachycardia—Niacin—atherosclerosis	0.000301	0.00305	CcSEcCtD
Iloperidone—Dyspnoea—Simvastatin—atherosclerosis	0.000299	0.00303	CcSEcCtD
Iloperidone—HRH1—connective tissue—atherosclerosis	0.000298	0.013	CbGeAlD
Iloperidone—Feeling abnormal—Lovastatin—atherosclerosis	0.000296	0.003	CcSEcCtD
Iloperidone—ADRA1A—adipose tissue—atherosclerosis	0.000296	0.0129	CbGeAlD
Iloperidone—ADRA2A—connective tissue—atherosclerosis	0.000293	0.0128	CbGeAlD
Iloperidone—Feeling abnormal—Ezetimibe—atherosclerosis	0.00029	0.00294	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00029	0.00294	CcSEcCtD
Iloperidone—Diarrhoea—Rosuvastatin—atherosclerosis	0.00029	0.00294	CcSEcCtD
Iloperidone—Fatigue—Simvastatin—atherosclerosis	0.000289	0.00293	CcSEcCtD
Iloperidone—Hypotension—Niacin—atherosclerosis	0.000288	0.00292	CcSEcCtD
Iloperidone—Body temperature increased—Lovastatin—atherosclerosis	0.000284	0.00288	CcSEcCtD
Iloperidone—ADRA2C—adipose tissue—atherosclerosis	0.000282	0.0123	CbGeAlD
Iloperidone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000281	0.00285	CcSEcCtD
Iloperidone—Dizziness—Rosuvastatin—atherosclerosis	0.00028	0.00284	CcSEcCtD
Iloperidone—Body temperature increased—Ezetimibe—atherosclerosis	0.000278	0.00282	CcSEcCtD
Iloperidone—Paraesthesia—Niacin—atherosclerosis	0.000277	0.00281	CcSEcCtD
Iloperidone—Feeling abnormal—Simvastatin—atherosclerosis	0.000277	0.0028	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000276	0.0028	CcSEcCtD
Iloperidone—Dyspnoea—Niacin—atherosclerosis	0.000275	0.00279	CcSEcCtD
Iloperidone—Somnolence—Niacin—atherosclerosis	0.000274	0.00278	CcSEcCtD
Iloperidone—Paraesthesia—Pravastatin—atherosclerosis	0.000272	0.00276	CcSEcCtD
Iloperidone—Dyspnoea—Pravastatin—atherosclerosis	0.000271	0.00274	CcSEcCtD
Iloperidone—Rash—Rosuvastatin—atherosclerosis	0.000267	0.00271	CcSEcCtD
Iloperidone—Dermatitis—Rosuvastatin—atherosclerosis	0.000267	0.0027	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Niacin—atherosclerosis	0.000266	0.0027	CcSEcCtD
Iloperidone—Body temperature increased—Simvastatin—atherosclerosis	0.000265	0.00269	CcSEcCtD
Iloperidone—Fatigue—Pravastatin—atherosclerosis	0.000262	0.00265	CcSEcCtD
Iloperidone—Asthenia—Lovastatin—atherosclerosis	0.000257	0.00261	CcSEcCtD
Iloperidone—Asthenia—Ezetimibe—atherosclerosis	0.000253	0.00256	CcSEcCtD
Iloperidone—SIGMAR1—liver—atherosclerosis	0.000252	0.011	CbGeAlD
Iloperidone—Nausea—Rosuvastatin—atherosclerosis	0.000252	0.00255	CcSEcCtD
Iloperidone—Feeling abnormal—Pravastatin—atherosclerosis	0.00025	0.00254	CcSEcCtD
Iloperidone—CYP2E1—cardiovascular system—atherosclerosis	0.000249	0.0109	CbGeAlD
Iloperidone—HTR2A—connective tissue—atherosclerosis	0.000249	0.0109	CbGeAlD
Iloperidone—Diarrhoea—Lovastatin—atherosclerosis	0.000246	0.00249	CcSEcCtD
Iloperidone—Body temperature increased—Niacin—atherosclerosis	0.000244	0.00247	CcSEcCtD
Iloperidone—Asthenia—Simvastatin—atherosclerosis	0.000241	0.00244	CcSEcCtD
Iloperidone—Diarrhoea—Ezetimibe—atherosclerosis	0.000241	0.00244	CcSEcCtD
Iloperidone—Body temperature increased—Pravastatin—atherosclerosis	0.00024	0.00243	CcSEcCtD
Iloperidone—Dizziness—Lovastatin—atherosclerosis	0.000237	0.00241	CcSEcCtD
Iloperidone—CYP3A5—adipose tissue—atherosclerosis	0.000236	0.0103	CbGeAlD
Iloperidone—Dizziness—Ezetimibe—atherosclerosis	0.000233	0.00236	CcSEcCtD
Iloperidone—Diarrhoea—Simvastatin—atherosclerosis	0.00023	0.00233	CcSEcCtD
Iloperidone—HRH1—adipose tissue—atherosclerosis	0.000229	0.01	CbGeAlD
Iloperidone—Rash—Lovastatin—atherosclerosis	0.000226	0.00229	CcSEcCtD
Iloperidone—Dermatitis—Lovastatin—atherosclerosis	0.000226	0.00229	CcSEcCtD
Iloperidone—ADRA2A—adipose tissue—atherosclerosis	0.000225	0.00983	CbGeAlD
Iloperidone—Dizziness—Simvastatin—atherosclerosis	0.000222	0.00225	CcSEcCtD
Iloperidone—Rash—Ezetimibe—atherosclerosis	0.000222	0.00225	CcSEcCtD
Iloperidone—Dermatitis—Ezetimibe—atherosclerosis	0.000222	0.00225	CcSEcCtD
Iloperidone—Asthenia—Niacin—atherosclerosis	0.000221	0.00224	CcSEcCtD
Iloperidone—Asthenia—Pravastatin—atherosclerosis	0.000218	0.00221	CcSEcCtD
Iloperidone—HTR2A—cardiovascular system—atherosclerosis	0.000217	0.00948	CbGeAlD
Iloperidone—HTR7—liver—atherosclerosis	0.000215	0.0094	CbGeAlD
Iloperidone—Nausea—Lovastatin—atherosclerosis	0.000213	0.00216	CcSEcCtD
Iloperidone—Rash—Simvastatin—atherosclerosis	0.000212	0.00215	CcSEcCtD
Iloperidone—Dermatitis—Simvastatin—atherosclerosis	0.000211	0.00214	CcSEcCtD
Iloperidone—Diarrhoea—Niacin—atherosclerosis	0.000211	0.00214	CcSEcCtD
Iloperidone—Nausea—Ezetimibe—atherosclerosis	0.000209	0.00212	CcSEcCtD
Iloperidone—Diarrhoea—Pravastatin—atherosclerosis	0.000208	0.00211	CcSEcCtD
Iloperidone—ADRA1A—liver—atherosclerosis	0.000207	0.00907	CbGeAlD
Iloperidone—Gefitinib—ALB—atherosclerosis	0.000204	0.0625	CrCbGaD
Iloperidone—Dizziness—Niacin—atherosclerosis	0.000204	0.00207	CcSEcCtD
Iloperidone—Dizziness—Pravastatin—atherosclerosis	0.000201	0.00203	CcSEcCtD
Iloperidone—Nausea—Simvastatin—atherosclerosis	0.000199	0.00202	CcSEcCtD
Iloperidone—ADRA2C—liver—atherosclerosis	0.000198	0.00864	CbGeAlD
Iloperidone—Rash—Niacin—atherosclerosis	0.000194	0.00197	CcSEcCtD
Iloperidone—Dermatitis—Niacin—atherosclerosis	0.000194	0.00197	CcSEcCtD
Iloperidone—Rash—Pravastatin—atherosclerosis	0.000191	0.00194	CcSEcCtD
Iloperidone—Dermatitis—Pravastatin—atherosclerosis	0.000191	0.00194	CcSEcCtD
Iloperidone—Nausea—Niacin—atherosclerosis	0.000183	0.00186	CcSEcCtD
Iloperidone—Nausea—Pravastatin—atherosclerosis	0.00018	0.00183	CcSEcCtD
Iloperidone—CYP1A2—liver—atherosclerosis	0.000171	0.0075	CbGeAlD
Iloperidone—CYP3A5—liver—atherosclerosis	0.000165	0.00723	CbGeAlD
Iloperidone—CYP2E1—liver—atherosclerosis	0.000154	0.00674	CbGeAlD
Iloperidone—HTR2A—liver—atherosclerosis	0.000134	0.00586	CbGeAlD
Iloperidone—CYP3A4—liver—atherosclerosis	0.000124	0.00543	CbGeAlD
Iloperidone—CYP2D6—liver—atherosclerosis	0.000122	0.00534	CbGeAlD
Iloperidone—CYP2E1—Metabolism—INS—atherosclerosis	3.64e-06	4.02e-05	CbGpPWpGaD
Iloperidone—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	3.64e-06	4.02e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—INS—atherosclerosis	3.64e-06	4.01e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—ALB—atherosclerosis	3.64e-06	4.01e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—INS—atherosclerosis	3.64e-06	4.01e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—IL6—atherosclerosis	3.63e-06	4.01e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	3.61e-06	3.99e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—LPL—atherosclerosis	3.61e-06	3.98e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—VEGFA—atherosclerosis	3.6e-06	3.97e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—VEGFA—atherosclerosis	3.6e-06	3.97e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCL2—atherosclerosis	3.59e-06	3.96e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IGF1—atherosclerosis	3.59e-06	3.96e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—IL6—atherosclerosis	3.58e-06	3.95e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	3.58e-06	3.95e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCL2—atherosclerosis	3.58e-06	3.95e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	3.58e-06	3.94e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—SCARB1—atherosclerosis	3.57e-06	3.94e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—INS—atherosclerosis	3.57e-06	3.94e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—STAT3—atherosclerosis	3.57e-06	3.94e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—STAT3—atherosclerosis	3.56e-06	3.93e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—STAT3—atherosclerosis	3.54e-06	3.91e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IGF1—atherosclerosis	3.53e-06	3.89e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—GPX1—atherosclerosis	3.52e-06	3.89e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IGF1—atherosclerosis	3.52e-06	3.88e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	3.51e-06	3.88e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	3.51e-06	3.87e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—NOS3—atherosclerosis	3.48e-06	3.84e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	3.45e-06	3.81e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MMP9—atherosclerosis	3.45e-06	3.81e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—VEGFA—atherosclerosis	3.45e-06	3.8e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CD36—atherosclerosis	3.43e-06	3.78e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—NFKB1—atherosclerosis	3.42e-06	3.77e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—STAT3—atherosclerosis	3.41e-06	3.76e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MAPK3—atherosclerosis	3.41e-06	3.76e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MMP9—atherosclerosis	3.41e-06	3.76e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MAPK3—atherosclerosis	3.4e-06	3.76e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	3.4e-06	3.76e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	3.38e-06	3.73e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.38e-06	3.72e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—NFKB1—atherosclerosis	3.37e-06	3.72e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MAPK8—atherosclerosis	3.36e-06	3.71e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.36e-06	3.7e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—AKT1—atherosclerosis	3.35e-06	3.7e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.35e-06	3.7e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—HMOX1—atherosclerosis	3.34e-06	3.69e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.34e-06	3.69e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—ALB—atherosclerosis	3.34e-06	3.69e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—ALB—atherosclerosis	3.33e-06	3.68e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.32e-06	3.66e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MAPK8—atherosclerosis	3.31e-06	3.66e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TGFB1—atherosclerosis	3.31e-06	3.65e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—AKT1—atherosclerosis	3.31e-06	3.65e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TGFB1—atherosclerosis	3.3e-06	3.64e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.28e-06	3.62e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.28e-06	3.62e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.28e-06	3.62e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.27e-06	3.6e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.26e-06	3.6e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MAPK3—atherosclerosis	3.26e-06	3.6e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.25e-06	3.59e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NOS3—atherosclerosis	3.25e-06	3.59e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.21e-06	3.54e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—APOB—atherosclerosis	3.2e-06	3.53e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.2e-06	3.53e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—NOS3—atherosclerosis	3.2e-06	3.53e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.19e-06	3.52e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PPARA—atherosclerosis	3.19e-06	3.52e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—NOS3—atherosclerosis	3.19e-06	3.52e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.18e-06	3.51e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	3.18e-06	3.51e-05	CbGpPWpGaD
Iloperidone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.17e-06	3.5e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TGFB1—atherosclerosis	3.16e-06	3.49e-05	CbGpPWpGaD
Iloperidone—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.16e-06	3.48e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	3.13e-06	3.45e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.12e-06	3.44e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GSTM1—atherosclerosis	3.12e-06	3.44e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.11e-06	3.43e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—VEGFA—atherosclerosis	3.1e-06	3.42e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AGT—atherosclerosis	3.09e-06	3.41e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—STAT3—atherosclerosis	3.07e-06	3.39e-05	CbGpPWpGaD
Iloperidone—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	3.07e-06	3.39e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—VEGFA—atherosclerosis	3.06e-06	3.38e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—LPL—atherosclerosis	3.06e-06	3.37e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	3.05e-06	3.36e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—STAT3—atherosclerosis	3.03e-06	3.34e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—APOE—atherosclerosis	3.03e-06	3.34e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	3.02e-06	3.33e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.01e-06	3.32e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CAV1—atherosclerosis	3e-06	3.31e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—APOA1—atherosclerosis	2.99e-06	3.3e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GPX1—atherosclerosis	2.98e-06	3.29e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	2.97e-06	3.28e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2.95e-06	3.26e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	2.94e-06	3.24e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MAPK3—atherosclerosis	2.93e-06	3.24e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	2.92e-06	3.23e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—atherosclerosis	2.92e-06	3.22e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—atherosclerosis	2.92e-06	3.22e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	2.91e-06	3.21e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CD36—atherosclerosis	2.91e-06	3.21e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MAPK3—atherosclerosis	2.9e-06	3.19e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	2.89e-06	3.19e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CXCL8—atherosclerosis	2.88e-06	3.18e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	2.88e-06	3.18e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	2.87e-06	3.17e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	2.87e-06	3.17e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	2.87e-06	3.16e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TGFB1—atherosclerosis	2.85e-06	3.14e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	2.84e-06	3.14e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	2.84e-06	3.13e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CXCL8—atherosclerosis	2.83e-06	3.12e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TGFB1—atherosclerosis	2.81e-06	3.1e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	2.8e-06	3.08e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	2.79e-06	3.08e-05	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	2.79e-06	3.07e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	2.78e-06	3.06e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—MTHFR—atherosclerosis	2.75e-06	3.04e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL6—atherosclerosis	2.74e-06	3.02e-05	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	2.74e-06	3.02e-05	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	2.73e-06	3.02e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	2.73e-06	3.01e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PPARA—atherosclerosis	2.7e-06	2.98e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—atherosclerosis	2.7e-06	2.98e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—atherosclerosis	2.69e-06	2.97e-05	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	2.68e-06	2.96e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.67e-06	2.94e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.65e-06	2.93e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.64e-06	2.91e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.64e-06	2.91e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PPARG—atherosclerosis	2.64e-06	2.91e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.63e-06	2.9e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AGT—atherosclerosis	2.62e-06	2.89e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.61e-06	2.88e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—INS—atherosclerosis	2.59e-06	2.85e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.58e-06	2.85e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.58e-06	2.85e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	2.58e-06	2.85e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.58e-06	2.85e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.57e-06	2.83e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—APOE—atherosclerosis	2.56e-06	2.83e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.56e-06	2.82e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	2.56e-06	2.82e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CAV1—atherosclerosis	2.54e-06	2.8e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.54e-06	2.8e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.54e-06	2.8e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—APOA1—atherosclerosis	2.53e-06	2.8e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.53e-06	2.79e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.53e-06	2.79e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.52e-06	2.78e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.51e-06	2.77e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.51e-06	2.77e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.5e-06	2.75e-05	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.49e-06	2.75e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—atherosclerosis	2.49e-06	2.75e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.49e-06	2.75e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—atherosclerosis	2.49e-06	2.75e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.49e-06	2.75e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.49e-06	2.74e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.48e-06	2.74e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.47e-06	2.73e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—APOB—atherosclerosis	2.47e-06	2.73e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.45e-06	2.71e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.45e-06	2.7e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.44e-06	2.7e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	2.44e-06	2.69e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.44e-06	2.69e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.44e-06	2.69e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.41e-06	2.65e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—atherosclerosis	2.38e-06	2.63e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ALB—atherosclerosis	2.37e-06	2.62e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	2.37e-06	2.61e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—LPL—atherosclerosis	2.36e-06	2.6e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—atherosclerosis	2.34e-06	2.58e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.33e-06	2.58e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—atherosclerosis	2.32e-06	2.56e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.31e-06	2.55e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.31e-06	2.55e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.3e-06	2.54e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GPX1—atherosclerosis	2.3e-06	2.54e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.3e-06	2.54e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—AKT1—atherosclerosis	2.3e-06	2.54e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—AKT1—atherosclerosis	2.3e-06	2.53e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.28e-06	2.52e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.28e-06	2.52e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.28e-06	2.51e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.27e-06	2.5e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—NOS3—atherosclerosis	2.27e-06	2.5e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.26e-06	2.5e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.26e-06	2.49e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CD36—atherosclerosis	2.24e-06	2.47e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.23e-06	2.46e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PPARG—atherosclerosis	2.23e-06	2.46e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK3—atherosclerosis	2.22e-06	2.44e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—AKT1—atherosclerosis	2.2e-06	2.43e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—INS—atherosclerosis	2.19e-06	2.42e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.18e-06	2.4e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.18e-06	2.4e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TGFB1—atherosclerosis	2.15e-06	2.37e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—atherosclerosis	2.15e-06	2.37e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.13e-06	2.35e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.13e-06	2.34e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—atherosclerosis	2.12e-06	2.33e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.11e-06	2.33e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.11e-06	2.33e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2.1e-06	2.31e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPARA—atherosclerosis	2.09e-06	2.3e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	2.08e-06	2.29e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.07e-06	2.29e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	2.07e-06	2.28e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—AKT1—atherosclerosis	2.03e-06	2.24e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AGT—atherosclerosis	2.02e-06	2.23e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ALB—atherosclerosis	2.01e-06	2.22e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.98e-06	2.19e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—AKT1—atherosclerosis	1.98e-06	2.18e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—APOE—atherosclerosis	1.98e-06	2.18e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—AKT1—atherosclerosis	1.97e-06	2.17e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CAV1—atherosclerosis	1.96e-06	2.16e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—APOA1—atherosclerosis	1.96e-06	2.16e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.95e-06	2.15e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.92e-06	2.12e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—NOS3—atherosclerosis	1.92e-06	2.12e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.84e-06	2.03e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.84e-06	2.02e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.79e-06	1.97e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.78e-06	1.97e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.76e-06	1.94e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPARG—atherosclerosis	1.72e-06	1.9e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.7e-06	1.88e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.69e-06	1.87e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—INS—atherosclerosis	1.69e-06	1.86e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.65e-06	1.82e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—atherosclerosis	1.62e-06	1.79e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—AKT1—atherosclerosis	1.6e-06	1.76e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.59e-06	1.76e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—atherosclerosis	1.59e-06	1.75e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.56e-06	1.72e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ALB—atherosclerosis	1.55e-06	1.71e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.49e-06	1.65e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NOS3—atherosclerosis	1.48e-06	1.64e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.47e-06	1.62e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—AKT1—atherosclerosis	1.47e-06	1.62e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.47e-06	1.62e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—AKT1—atherosclerosis	1.47e-06	1.62e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.45e-06	1.6e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.44e-06	1.59e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.36e-06	1.5e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.34e-06	1.48e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AKT1—atherosclerosis	1.04e-06	1.15e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AKT1—atherosclerosis	8.83e-07	9.74e-06	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AKT1—atherosclerosis	6.81e-07	7.52e-06	CbGpPWpGaD
